EMA Authorised: Vizamyl (flutemetamol (18F)) — GE Healthcare AS

View source ↗

Summary

EMA authorised Vizamyl (flutemetamol (18F)) for radionuclide PET imaging in adults being evaluated for Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• VIZAMYL (Flutemetamol F-18)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Alzheimer Disease. MAH: GE Healthcare AS. Decision date: 13/03/2026